1 / 13

CLL - characteristic

Chronic Lymphocytic Leukemia (CLL) DEFINITION CLL is a neoplastic disease characterized by proliferation and accumulation ( blood, marrow and lymphoid organs ) of morphologically mature but immunologically dysfunctional l ymphocytes. CLL - characteristic.

hiram-case
Télécharger la présentation

CLL - characteristic

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic Lymphocytic Leukemia (CLL)DEFINITIONCLL is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid organs) of morphologically mature but immunologically dysfunctional lymphocytes

  2. CLL - characteristic • Disease of elderly (50-60 years) • 2:1 ratio of male to female • Most common adult leukemia in Europe and USA (USA: 3/100.000 population) • In 98% of cases leukemic cells are monoclonal population of immature B lymphocytes with low-density surface immunoglobulin • Etiology unknown

  3. CLL – clinical features • Most of patients: fatigue, reduced exercises tolerance, weight loss, fever, recurrent infections, sweats, bleeding • 25% of patients: asymptomatic • 80% of patients : nontender lymphadenopaty • 50% of patients: splenomegaly • Hepatomegaly

  4. CLL - diagnostic features a) Blood test lymphocytosis ≥ 5G/l (4 weeks) b) Morphology monoconal population of small mature lymphocyte c) B-cell CLL phenotype clonal CD5+/CD19+ population of lymphocyte d) Markers of clonality κ/λ light chain restriction; cytogenetical abnormalities e) Bone marrow infiltrate > 30% of nuceated cells on aspirate f) Lymph node diffuse infiltrate of small lymphocye

  5. CLL – diagnosis (2) • Blood test • anaemia • trombocytopenia • smudge cells in peripheral blood film • Lymh node histology: diffuse infiltrate of small lymphocyte • Bone marrow histology • interstitial infiltration (30% - good prognosis) • diffuse involvement (25% - poor prognosis) • nodular involvement • Hypogammaglobulinemia • Cytogenetic abnormalities (FISH – 90%) • 13q-; 11q-; +12q; 17p-; 6q- • Molecular abnormalities • p53; bcl2

  6. CLL – clinical staging (1) RAI CLINICAL STAGING SYSTEM • Stage Clinical Features at Diagnosis Median Survival (m) ________________________________________________________________________ • Low risk • 0 Blood (> 5.000/ul. monoclonal lymphocytes) >150 • and marrow (>30%) lymphocytosis • Intermediate risk • I Lymphocytosis and enlarged lymph nodes > 101 • II Lymphocytosis and enlarged spleen and/or liver > 71 • High risk • III Lymphocytosis and anemia (Hgb < 11g/dL) > 19 • IV Lymphocytosis and thrombocytopenia (Plt < 100.000/ul.) > 19

  7. CLL – Rai stages

  8. CLL – clinical staging (2) BINET CLINICAL STAGING SYSTEM • Stage Clinical Features at Diagnosis Median Survival (m) ____________________________________________________________________ • A Blood (> 5.000/ul. monoclonal lymphocytes) > 84 • and marrow (>30%) lymphocytosis and less • than 3 areasof palpable lymphoid-tissue enlargement • B Lymphocytosis and 3 and more areasof palpable < 60 • lymphoid-tissue enlargement • C Lymphocytosis with anemia (Hgb <11g/dL; < 24 • women <10g/dL) • or thrombocytopenia (Plt <100.000/uL) • ___________________________________________________________________ An area: cervical, axillary, inguinal/femoral, spleen, liver

  9. CLL – Binet stages

  10. CLL – prognostic factors • clinical stage • marrow histology (diffuse marrow involvement - poor prognosis) • leukemia cell doubling time • CD38 expression • IgVH mutational status • ZAP-70 expression • FISH cytogenetic • low-risk: normal kariotype; isolated del(13q) • high-risk: del(17p0, del(11q), trisomy 12 • serum markers:2-microglobulin; thymidine- kinase, sCD23

  11. CLL : ZAP-70

  12. CLL – treatment (1) • Watch and wait • Monotherapy • glucocorticoids • alkylating agents (Chlorambucil, Cyclophosphamide) • purine analogues (Fludarabine, Cladribine, Pentostatin) • Combination chemotherapy • Chlorambucil/ Cyclophosphamide + Prednisone • Fludarabine + Cyclophosphamide +/- Mitoxantrone • CVP, CHOP • Monoclonal antibodies (monotherapy and in combination) • Alemtuzumab (anti-CD52) • Rituximab (anti-CD20) • Splenectomy • Radiotherapy

  13. CLL – treatment (2) • Hematopoietic stem cell transplantation • allogeneic with reduced intesity conditioning • autologous • New and novel agents • Oblimersen – bcl2-directed antisense oligonucleotide • Lenalidomide • Flavopiridol • Anti-CD23 • Anti-CD40 • Vaccine strategies • Supportive therapy(allopurinol, G-CSF, blood and platelet transfusion, immunoglobulins, antibiotics)

More Related